Dendreon Corp fka DNDNQ

[walldiver]

Sorry, I'll have to disagree as well. I stated that program survival bias is a plausible theory, but it's less likely to occur if your nonpivotal Phase 2/3 trials are randomized. In other words, randomizing your earlier trials gives you a better idea if your drug works. This is something that responsible biotechs should do, instead of data-mining your Phase 3 (first randomized trial) in order to find a subgroup that saw success.